WO2020147472A8 - 赤红球菌产品及其制药用途 - Google Patents

赤红球菌产品及其制药用途 Download PDF

Info

Publication number
WO2020147472A8
WO2020147472A8 PCT/CN2019/125180 CN2019125180W WO2020147472A8 WO 2020147472 A8 WO2020147472 A8 WO 2020147472A8 CN 2019125180 W CN2019125180 W CN 2019125180W WO 2020147472 A8 WO2020147472 A8 WO 2020147472A8
Authority
WO
WIPO (PCT)
Prior art keywords
rhodococcus ruber
product derived
pharmaceutical use
ruber
rhodococcus
Prior art date
Application number
PCT/CN2019/125180
Other languages
English (en)
French (fr)
Other versions
WO2020147472A1 (zh
Inventor
盖波
窦春艳
张轶
张国英
Original Assignee
辽宁格瑞仕特生物制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 辽宁格瑞仕特生物制药有限公司 filed Critical 辽宁格瑞仕特生物制药有限公司
Priority to US17/421,717 priority Critical patent/US20220241348A1/en
Priority to EP19910829.1A priority patent/EP3913045A4/en
Priority to KR1020217025000A priority patent/KR20210114436A/ko
Priority to CN201980010257.6A priority patent/CN111727235B/zh
Priority to JP2021539949A priority patent/JP2022516983A/ja
Publication of WO2020147472A1 publication Critical patent/WO2020147472A1/zh
Publication of WO2020147472A8 publication Critical patent/WO2020147472A8/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

一种分离的赤红球菌、源自赤红球菌的产品(尤其是源自赤红球菌细胞壁的产品)、赤红球菌产品的制备方法、以及赤红球菌产品在预防和/或治疗扁平苔藓中的用途。赤红球菌产品有效减小扁平苔藓的糜烂面积，降低疼痛程度。
PCT/CN2019/125180 2019-01-15 2019-12-13 赤红球菌产品及其制药用途 WO2020147472A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US17/421,717 US20220241348A1 (en) 2019-01-15 2019-12-13 Product derived from rhodococcus ruber, and pharmaceutical use thereof
EP19910829.1A EP3913045A4 (en) 2019-01-15 2019-12-13 PRODUCT DERIVED FROM RHODOCOCCUS RUBER, AND PHARMACEUTICAL USE THEREOF
KR1020217025000A KR20210114436A (ko) 2019-01-15 2019-12-13 로도코커스 루버로부터 유래하는 생성물 및 이의 약학 용도
CN201980010257.6A CN111727235B (zh) 2019-01-15 2019-12-13 赤红球菌产品及其制药用途
JP2021539949A JP2022516983A (ja) 2019-01-15 2019-12-13 ロドコッカス・ルーバー製品及びその製薬使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910036001 2019-01-15
CN201910036001.4 2019-01-15
CN201911022193 2019-10-25
CN201911022193.X 2019-10-25

Publications (2)

Publication Number Publication Date
WO2020147472A1 WO2020147472A1 (zh) 2020-07-23
WO2020147472A8 true WO2020147472A8 (zh) 2020-09-10

Family

ID=71613086

Family Applications (8)

Application Number Title Priority Date Filing Date
PCT/CN2019/125180 WO2020147472A1 (zh) 2019-01-15 2019-12-13 赤红球菌产品及其制药用途
PCT/CN2019/125598 WO2020147475A1 (zh) 2019-01-15 2019-12-16 赤红球菌产品在治疗复发性阿弗他溃疡中的用途
PCT/CN2019/126969 WO2020147511A1 (zh) 2019-01-15 2019-12-20 赤红球菌产品在治疗温血动物的皮肤损伤或溃疡中的用途
PCT/CN2019/127895 WO2020147530A1 (zh) 2019-01-15 2019-12-24 分离的赤红球菌细胞壁骨架在制备治疗人乳头瘤病毒感染的药物中的用途
PCT/CN2019/128237 WO2020147532A1 (zh) 2019-01-15 2019-12-25 分离的赤红球菌细胞壁骨架在制备治疗人宫颈癌前病变的药物中的用途
PCT/CN2019/128238 WO2020147533A1 (zh) 2019-01-15 2019-12-25 分离的赤红球菌细胞壁骨架在制备治疗单纯疱疹和/或带状疱疹的药物中的用途
PCT/CN2019/128656 WO2020147547A1 (zh) 2019-01-15 2019-12-26 分离的赤红球菌细胞壁骨架在制备治疗宫颈糜烂的药物中的用途
PCT/CN2019/129891 WO2020147570A1 (zh) 2019-01-15 2019-12-30 赤红球菌产品在治疗白色念珠菌感染引起的疾病中的用途

Family Applications After (7)

Application Number Title Priority Date Filing Date
PCT/CN2019/125598 WO2020147475A1 (zh) 2019-01-15 2019-12-16 赤红球菌产品在治疗复发性阿弗他溃疡中的用途
PCT/CN2019/126969 WO2020147511A1 (zh) 2019-01-15 2019-12-20 赤红球菌产品在治疗温血动物的皮肤损伤或溃疡中的用途
PCT/CN2019/127895 WO2020147530A1 (zh) 2019-01-15 2019-12-24 分离的赤红球菌细胞壁骨架在制备治疗人乳头瘤病毒感染的药物中的用途
PCT/CN2019/128237 WO2020147532A1 (zh) 2019-01-15 2019-12-25 分离的赤红球菌细胞壁骨架在制备治疗人宫颈癌前病变的药物中的用途
PCT/CN2019/128238 WO2020147533A1 (zh) 2019-01-15 2019-12-25 分离的赤红球菌细胞壁骨架在制备治疗单纯疱疹和/或带状疱疹的药物中的用途
PCT/CN2019/128656 WO2020147547A1 (zh) 2019-01-15 2019-12-26 分离的赤红球菌细胞壁骨架在制备治疗宫颈糜烂的药物中的用途
PCT/CN2019/129891 WO2020147570A1 (zh) 2019-01-15 2019-12-30 赤红球菌产品在治疗白色念珠菌感染引起的疾病中的用途

Country Status (6)

Country Link
US (2) US20220241348A1 (zh)
EP (2) EP3913045A4 (zh)
JP (2) JP2022516983A (zh)
KR (2) KR20210114436A (zh)
CN (8) CN111727235B (zh)
WO (8) WO2020147472A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109576180B (zh) * 2018-12-17 2021-11-26 北京利昂盛生物技术有限公司 一株赤红球菌及其作为免疫佐剂在制备疫苗中的应用
EP3913045A4 (en) * 2019-01-15 2022-12-28 Liaoning Greatest Bio-Pharmaceutical Co., Ltd. PRODUCT DERIVED FROM RHODOCOCCUS RUBER, AND PHARMACEUTICAL USE THEREOF
WO2020182180A1 (zh) * 2019-03-14 2020-09-17 辽宁格瑞仕特生物制药有限公司 赤红球菌产品在治疗外阴白色病变中的用途
JP2022531109A (ja) * 2019-04-24 2022-07-06 ▲遼▼▲寧▼格瑞仕特生物制▲藥▼有限公司 熱損傷の治療におけるロドコッカスルーバー製品の使用
CN110101721A (zh) * 2019-05-21 2019-08-09 福建省微生物研究所 一种赤红球菌提取物的用途
JP2023510232A (ja) * 2020-01-21 2023-03-13 ▲遼▼▲寧▼格瑞仕特生物制▲藥▼有限公司 ロドコッカス・ルーバーの細胞壁骨格の再生医学における用途
WO2022199453A1 (zh) * 2021-03-24 2022-09-29 辽宁格瑞仕特生物制药有限公司 赤红球菌产品在治疗放射病中的用途
CN115025128A (zh) * 2022-06-24 2022-09-09 辽宁格瑞仕特生物制药有限公司 红色诺卡氏菌细胞壁骨架在治疗宫颈病变中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63126493A (ja) * 1986-11-17 1988-05-30 Nippon Oil & Fats Co Ltd 抗ウイルス剤
WO2000009659A1 (de) * 1998-08-13 2000-02-24 Lonza Ag Verfahren zur herstellung von indanderivaten
ES2280325T3 (es) * 2001-06-22 2007-09-16 Institut Francais Du Petrole Conjunto de genes del citocromo p-450 de rhodococcus ruber y uso del mismo en la escision de combustible de tipo eter.
DE10149715B4 (de) * 2001-10-09 2013-04-18 Evonik Degussa Gmbh Esterase EstA aus Rhodococcus ruber
CN1291725C (zh) * 2002-03-08 2006-12-27 沈阳胜宝康生物制药有限公司 用于治疗宫颈糜烂的红色诺卡氏菌细胞壁骨架制剂及其制法
CN1214798C (zh) * 2002-06-21 2005-08-17 沈阳胜宝康生物制药有限公司 用于治疗单纯疱疹和带状疱疹的诺卡软膏
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
GB0220809D0 (en) * 2002-09-06 2002-10-16 Univ College Of London Immune modulator
PT1534330E (pt) * 2002-09-06 2014-06-23 Ucl Business Plc Células bacterianas inteiras como moduladores imunitários
CN1223673C (zh) 2003-01-23 2005-10-19 中国科学院微生物研究所 一种产生生物乳化剂和降解多环芳烃的赤红球菌Em及用途
GB2422544B (en) * 2003-11-14 2008-05-14 Ucl Biomedica Plc Immune modulator
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
CN1879661B (zh) * 2005-06-16 2012-06-20 辽宁纳可佳生物制药有限公司 红色诺卡氏菌细胞壁骨架在制备抗真菌感染的药物中的用途
GB0526032D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Use
CN100519737C (zh) 2006-04-29 2009-07-29 浙江工业大学 赤红球菌zjb-064及其应用
CN101073583A (zh) * 2006-05-19 2007-11-21 沈阳胜宝康生物制药有限公司 红色诺卡氏菌细胞壁骨架在制备药物中的用途
CN101209267B (zh) * 2006-12-29 2012-10-03 辽宁纳可佳生物制药有限公司 红色诺卡氏菌细胞壁骨架在制备治疗皮肤损伤和疮疡的药物中的用途
JP5019519B2 (ja) * 2007-03-20 2012-09-05 独立行政法人産業技術総合研究所 ロドコッカス属細菌由来の抗菌活性物質及びそれを用いた微生物防除法
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
CN101250490A (zh) 2008-03-28 2008-08-27 天津科技大学 活酵母细胞衍生物的生产方法
CN101580808B (zh) 2008-05-15 2011-11-16 汕头大学 一株赤红球菌及其在降解烃类化合物中的应用
CN101323865B (zh) 2008-08-07 2012-07-18 山东省科学院能源研究所 微生物油脂分离提取方法
CN101619299B (zh) 2009-07-08 2012-07-04 天津科技大学 一种赤红球菌以及利用该菌制备5-氰基戊酰胺的方法
CN101892283A (zh) * 2010-06-03 2010-11-24 华东理工大学 红球菌Rhodococcus ruber 4.1187催化制备光学纯(S)-(+)-2-苯基丙酸
CN102250796B (zh) 2011-06-21 2013-11-06 中国农业科学院农业环境与可持续发展研究所 一种赤红球菌和微生物菌剂及它们的应用
CN102604875B (zh) 2012-03-26 2014-12-10 江西师范大学 赤红球菌及其在降解苯酚污染物中的应用
JP6238366B2 (ja) * 2012-08-28 2017-11-29 国立大学法人北海道大学 非極性溶媒に分散性を有する細菌菌体成分を内封する脂質膜構造体およびその製造方法
CN102895264B (zh) * 2012-11-15 2014-05-14 福建广生堂药业股份有限公司 红色诺卡氏菌细胞壁骨架口含片及其制备方法
CN103160491B (zh) 2013-04-15 2014-12-10 江西师范大学 赤红球菌sd3的诱变菌m1的固定化细胞及其在降解苯酚污染物中的应用
CN103509833B (zh) 2013-08-15 2016-04-06 天津科技大学 一种利用赤红球菌制备2,6-二氟苯甲酰胺的方法
CN103627653B (zh) 2013-10-17 2016-01-20 浙江省环境保护科学设计研究院 一种赤红球菌菌株及其在含有机污染物的废水处理中的应用
CN104830738B (zh) 2015-05-22 2017-09-15 厦门大学 一种赤红球菌及其在制备十溴联苯醚降解剂中的应用
CN106591168B (zh) 2016-02-02 2019-08-16 江苏南资环保科技有限公司 一种烟嘧磺隆降解赤红球菌ymhl-1及其应用
CA3015688A1 (en) * 2016-02-25 2017-08-31 Thomas Julius Borody Compositions and methods of treatment of chronic infectious diseases
CN106591172B (zh) 2016-04-01 2019-11-29 江苏南资环保科技有限公司 一种赤红球菌pta-2及其固定化和应用
CN105820982B (zh) 2016-04-29 2019-06-28 河北省科学院生物研究所 一种赤红球菌xs-2、其生物菌剂及制备方法和应用
CN106434466B (zh) 2016-10-14 2019-10-18 天津科技大学 一种产生天然红色素的赤红球菌及其制备方法与应用
CN107151635B (zh) 2017-04-28 2020-02-18 中国农业科学院研究生院 一种能够降解邻苯二甲酸酯的赤红球菌及其应用
CN108815197A (zh) * 2017-05-03 2018-11-16 辽宁格瑞仕特生物制药有限公司 红色诺卡氏菌细胞壁骨架作为cd4+t细胞增殖促进剂的用途
CN108938674A (zh) * 2017-05-27 2018-12-07 福建省山河药业有限公司 红色诺卡氏菌细胞壁骨架在制备治疗皮肤病变药物中的用途
CN108130288B (zh) 2017-12-15 2020-10-09 浙江工业大学 赤红球菌及其降解有机污染物的应用
CN108862590B (zh) 2018-08-03 2021-01-12 中国石油大学(北京) 一种降解丙烯腈废水cod的方法
CN109576180B (zh) 2018-12-17 2021-11-26 北京利昂盛生物技术有限公司 一株赤红球菌及其作为免疫佐剂在制备疫苗中的应用
CN109666609B (zh) * 2019-01-14 2020-04-17 付家栋 一种赤红球菌发酵方法及其作为佐剂在动物疫苗中的应用
EP3913045A4 (en) * 2019-01-15 2022-12-28 Liaoning Greatest Bio-Pharmaceutical Co., Ltd. PRODUCT DERIVED FROM RHODOCOCCUS RUBER, AND PHARMACEUTICAL USE THEREOF
WO2020182180A1 (zh) * 2019-03-14 2020-09-17 辽宁格瑞仕特生物制药有限公司 赤红球菌产品在治疗外阴白色病变中的用途
JP2022531109A (ja) * 2019-04-24 2022-07-06 ▲遼▼▲寧▼格瑞仕特生物制▲藥▼有限公司 熱損傷の治療におけるロドコッカスルーバー製品の使用
CN110184215B (zh) * 2019-05-21 2021-08-13 福建省微生物研究所 一种赤红球菌菌株、菌制剂及其菌体细胞与提取物的应用
JP2023510232A (ja) * 2020-01-21 2023-03-13 ▲遼▼▲寧▼格瑞仕特生物制▲藥▼有限公司 ロドコッカス・ルーバーの細胞壁骨格の再生医学における用途
WO2022199453A1 (zh) * 2021-03-24 2022-09-29 辽宁格瑞仕特生物制药有限公司 赤红球菌产品在治疗放射病中的用途

Also Published As

Publication number Publication date
JP2022516984A (ja) 2022-03-03
WO2020147472A1 (zh) 2020-07-23
WO2020147533A8 (zh) 2020-09-10
CN111801105A (zh) 2020-10-20
CN111801105B (zh) 2022-05-10
CN111727236A (zh) 2020-09-29
CN111727235B (zh) 2024-03-15
WO2020147530A1 (zh) 2020-07-23
WO2020147533A1 (zh) 2020-07-23
WO2020147475A8 (zh) 2020-09-10
WO2020147530A8 (zh) 2020-09-10
JP2022516983A (ja) 2022-03-03
CN111787931B (zh) 2023-09-29
US20220241348A1 (en) 2022-08-04
WO2020147511A8 (zh) 2020-09-10
US20220265729A1 (en) 2022-08-25
WO2020147532A1 (zh) 2020-07-23
EP3913045A1 (en) 2021-11-24
WO2020147475A1 (zh) 2020-07-23
CN111727048B (zh) 2023-11-28
EP3909595A4 (en) 2022-02-23
CN111712249A (zh) 2020-09-25
KR20210114436A (ko) 2021-09-23
CN111727048A (zh) 2020-09-29
EP3909595A1 (en) 2021-11-17
CN111867606A (zh) 2020-10-30
WO2020147547A1 (zh) 2020-07-23
WO2020147570A1 (zh) 2020-07-23
KR20210114966A (ko) 2021-09-24
WO2020147511A1 (zh) 2020-07-23
CN111787931A (zh) 2020-10-16
EP3913045A4 (en) 2022-12-28
CN111801106A (zh) 2020-10-20
CN111727235A (zh) 2020-09-29

Similar Documents

Publication Publication Date Title
WO2020147472A8 (zh) 赤红球菌产品及其制药用途
WO2005030200A8 (ja) 自己免疫疾患治療剤
WO2005012294A8 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
SG163567A1 (en) Treatment of tumors
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
WO2008021113A3 (en) Transdermal methods and systems for treating alzheimer's disease
WO2007050294A3 (en) Liquid dosage forms having enteric properties of delayed and then sustained release
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
MX2021007069A (es) 3,3-difluoroalilaminas o sales de las mismas y composiciones farmaceuticas que comprenden las mismas.
WO2010058926A3 (ko) 생강 추출물 또는 쇼가올을 포함하는 약학 조성물
MX2022002196A (es) Composición de liberación retardada de niclosamida y uso antiviral de la misma.
EP4342461A3 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
MXPA04001397A (es) Metodo y composiciones para el tratamiento y prevencion de dolor e inflamacion con un inhibidor selectivo de cicloxigenasa-2 y sulfato de condroitina.
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
WO2003059329A3 (en) Polytartrate composition
EP3964520A4 (en) NEW OLIGOPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER USING IT AS AN ACTIVE SUBSTANCE
WO2004087066A3 (en) Hif-1 inhibitors
EP3989805A4 (en) DEVICES, SYSTEMS AND METHODS FOR THE TREATMENT OF BLOCKAGED EYE GLANDS
MX2022003945A (es) Metodo para tratar vih con cabotegravir y rilpivirina.
WO2017140684A3 (en) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
EP3955927A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT, MITIGATION AND PREVENTION OF H. PYLORI INFECTION
EP3946002A4 (en) SYSTEMS AND METHODS FOR CORNEAL TOPOGRAPHY
WO2020005189A3 (en) Solid oral pharmaceutical compositions comprising teriflunomide
WO2004069155A3 (en) Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof
HRP20230693T1 (hr) Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19910829

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021539949

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20217025000

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019910829

Country of ref document: EP

Effective date: 20210816